Reimagining Amyloid-β Pathway Modulation: Strategic Guida...
2025-10-21
This thought-leadership article explores the mechanistic underpinnings, experimental validation, and translational strategy for BACE1 inhibition in Alzheimer’s disease research. Focusing on Lanabecestat (AZD3293)—a blood-brain barrier-penetrant, orally active BACE1 inhibitor—the piece synthesizes recent evidence, such as the synaptic-sparing effects of moderate β-secretase inhibition, and positions Lanabecestat as an enabling tool for next-generation neurodegenerative disease models. The narrative escalates beyond standard product information by offering strategic, evidence-based guidance for translational research teams.